… Amyotrophic lateral sclerosis (ALS) is a neurodegenerative … Patients with amyotrophic
lateral sclerosis (ALS) may have a … Current treatments only have a small effect on progression, …

… with Amyotrophic Lateral Sclerosis, the … Amyotrophic Lateral Sclerosis experienced that
treatment with MI-E was exhausting and inefficient. Despite adjustments of settings, all treatment …

… Moving stem cells research from bench to bedside requires a thorough knowledge of
their … of unproven treatments to patients outside clinical trial and drug agencies’ approval [43]. …

… in the non-pharmacological therapy trials in ALS. Currently, no therapeutic effort seems to
be … , but recent findings in ALS will certainly help in the discovery of an effective treatment. …

… cell therapy for ALS holds great promise. Throughout its development from bench to bedside,
… and patients’ safety, advocating good clinical trial design to truly assess treatment efficacy. …

… treatment of spasticity in ALS patients, as they can control spasticity with safety and efficacy
in multiple sclerosis [58… cohort study has revealed high treatment satisfaction with nabiximols, …

… Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that affects adults and
… from bench to bedside in the field of ALS treatment. More than 160 drug candidates or ther…

Amyotrophic lateral sclerosis (ALS) is a motor neuron disease characterized by progressive
loss of upper and lower motor neurons. Despite significant scientific efforts in the last …

… its safety and efficacy and its use as a complementary therapy along with other approved
drugs. … Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded …

… This opposes the high attrition of drugs during bench-to-bedside translation … drug development.
These findings emphasize a careful application of these model systems for ALS therapy …